Cover Image
市場調查報告書

沙眼衣原體感染:開發中產品分析

Chlamydia Infections - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 200439
出版日期 內容資訊 英文 76 Pages
訂單完成後即時交付
價格
Back to Top
沙眼衣原體感染:開發中產品分析 Chlamydia Infections - Pipeline Review, H2 2016
出版日期: 2016年09月21日 內容資訊: 英文 76 Pages
簡介

沙眼衣原體感染是因細菌而引起的傳染性病。症狀有排尿時的刺痛感,陰莖和陰道有膿一般的分泌物,下腹部疼痛,非經期的出血及疼痛,睪丸週邊的腫起等。原因有年齡,非特定多數的性交對象,性感染疾病的病史等。治療方法有使用抗生素和止痛藥等。

本報告提供沙眼衣原體感染的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等資訊,為您概述為以下內容。

目錄

簡介

沙眼衣原體感染概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

研究中的治療藥:各大學/研究機關

開發中產品的概要

  • 後期階段的產品
  • 初期階段的產品

開發中的產品:各企業

研究中的產品:各大學/研究機關

開發治療藥的企業

  • Abera Bioscience AB
  • Genocea Biosciences, Inc.
  • Lead Discovery Center GmbH
  • Merck & Co., Inc.
  • NanoBio Corporation
  • Prokarium Limited
  • QureTech Bio AB
  • SATT IDF Innov SAS
  • Selecta Biosciences, Inc.
  • SIGA Technologies, Inc.
  • Statens Serum Institut
  • Vault Pharma Inc.

治療藥的評估

  • 單獨療法的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

暫停的計劃

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8481IDB

Summary

Global Markets Direct's, 'Chlamydia Infections - Pipeline Review, H2 2016', provides an overview of the Chlamydia Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chlamydia Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chlamydia Infections and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Chlamydia Infections
  • The report reviews pipeline therapeutics for Chlamydia Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Chlamydia Infections therapeutics and enlists all their major and minor projects
  • The report assesses Chlamydia Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Chlamydia Infections

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Chlamydia Infections
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Chlamydia Infections pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Chlamydia Infections Overview
  • Therapeutics Development
    • Pipeline Products for Chlamydia Infections - Overview
    • Pipeline Products for Chlamydia Infections - Comparative Analysis
  • Chlamydia Infections - Therapeutics under Development by Companies
  • Chlamydia Infections - Therapeutics under Investigation by Universities/Institutes
  • Chlamydia Infections - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Chlamydia Infections - Products under Development by Companies
  • Chlamydia Infections - Products under Investigation by Universities/Institutes
  • Chlamydia Infections - Companies Involved in Therapeutics Development
    • Abera Bioscience AB
    • Genocea Biosciences, Inc.
    • Lead Discovery Center GmbH
    • Merck & Co., Inc.
    • NanoBio Corporation
    • Prokarium Limited
    • QureTech Bio AB
    • SATT IDF Innov SAS
    • Selecta Biosciences, Inc.
    • SIGA Technologies, Inc.
    • Statens Serum Institut
    • Vault Pharma Inc.
  • Chlamydia Infections - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • Ab-03 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • acALY-18 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Chlamydia trachomatis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Chlamydia trachomatis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Chlamydia vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • chlamydia vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Chlamydia vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Chlamydia vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Chlamydia vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Chlamydia vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GEN-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Peptides to Inhibit CPAF for Chlamydia Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Chlamydia Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Chlamydophila Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Block Virulence for Chlamydia Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • solithromycin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ST-669 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VPI-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Chlamydia Infections - Dormant Projects
  • Chlamydia Infections - Product Development Milestones
    • Featured News & Press Releases
      • Dec 02, 2015: NanoBio's Chlamydia Vaccine Improves Clearance of Bacteria and Prevents Pelvic Inflammatory Disease in Mice
      • Aug 03, 2015: New Vaccine For Chlamydia to Use Synthetic Biology
      • Aug 03, 2015: SynbiCITE funds new vaccine for Chlamydia
      • Aug 12, 2014: Cempra Initiates Phase 3 Clinical Trial in Patients With Uncomplicated Gonorrhea Infection
      • Jul 20, 2011: Newly Designed Molecule Blocks Chlamydia Bacteria
      • Dec 15, 2009: Genocea Biosciences Awarded Grant For The Development Of Chlamydia Vaccines From The University Of Pittsburgh Medical Center's Sexually Transmitted Infections Cooperative Research Center
      • Sep 13, 2007: Possible Vaccine Target For Chlamydia Identified
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Chlamydia Infections, H2 2016
  • Number of Products under Development for Chlamydia Infections - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Chlamydia Infections - Pipeline by Abera Bioscience AB, H2 2016
  • Chlamydia Infections - Pipeline by Genocea Biosciences, Inc., H2 2016
  • Chlamydia Infections - Pipeline by Lead Discovery Center GmbH, H2 2016
  • Chlamydia Infections - Pipeline by Merck & Co., Inc., H2 2016
  • Chlamydia Infections - Pipeline by NanoBio Corporation, H2 2016
  • Chlamydia Infections - Pipeline by Prokarium Limited, H2 2016
  • Chlamydia Infections - Pipeline by QureTech Bio AB, H2 2016
  • Chlamydia Infections - Pipeline by SATT IDF Innov SAS, H2 2016
  • Chlamydia Infections - Pipeline by Selecta Biosciences, Inc., H2 2016
  • Chlamydia Infections - Pipeline by SIGA Technologies, Inc., H2 2016
  • Chlamydia Infections - Pipeline by Statens Serum Institut, H2 2016
  • Chlamydia Infections - Pipeline by Vault Pharma Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Chlamydia Infections - Dormant Projects, H2 2016
  • Chlamydia Infections - Dormant Projects (Contd..1), H2 2016

List of Figures

  • Number of Products under Development for Chlamydia Infections, H2 2016
  • Number of Products under Development for Chlamydia Infections - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top